Business Context and Reporting Period
Company: Syndax Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 18, 2018
Event: Unregistered Sales of Equity Securities (Item 3.02)
Key Transaction Details
On June 18, 2018, the Company entered into an Exchange Agreement with entities affiliated with Biotechnology Value Fund, L.P. (the "Exchanging Stockholders"). The Company exchanged 2,000,000 shares of its common stock owned by these stockholders for pre-funded warrants (the "Exchange Warrants") to purchase an aggregate of 2,000,000 shares of Common Stock.
- Exercise Price: $0.0001 per share.
- Expiration: Twenty years from the date of issuance.
- Voting Rights: Holders do not have voting rights except as required by Delaware law.
- Ownership Limitation: Warrants cannot be exercised if the Exchanging Stockholders would beneficially own more than 9.99% of the Common Stock, subject to exceptions.
- Registration Status: Issued without registration under the Securities Act of 1933, relying on the Section 3(a)(9) exemption.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific equity transaction and does not contain financial statements or performance metrics.
Material Changes
The primary material change is the conversion of 2,000,000 shares of common stock held by specific affiliates into pre-funded warrants. This transaction alters the capital structure by replacing direct equity holdings with warrant instruments for the Exchanging Stockholders.
Guidance, Outlook, and Risks
Management Commentary: The filing states that representations, warranties, and covenants made in the Exchange Agreement were made solely for the benefit of the parties to the agreement and should not be deemed representations to investors. These statements should not be relied upon as accurately representing the current state of the Company's affairs.
Risks and Contingencies: The filing notes that the description of the Exchange Agreement and Warrants is qualified in its entirety by reference to the full documents filed as Exhibits 10.1 and 4.1.
Investor Verification Checklist
- Verify the full terms of the Exchange Agreement and Warrant Agreement in Exhibits 10.1 and 4.1.
- Confirm the current beneficial ownership percentage of the Exchanging Stockholders to understand the 9.99% exercise limitation.
- Review the Company's most recent 10-Q or 10-K for financial performance data, as this 8-K does not contain financial metrics.
- Assess the impact of the pre-funded warrants on potential future dilution upon exercise.